Michael W. Deininger
Impact in
- Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 352
- Chronic Myeloid Leukemia Treatments 322
- Acute Myeloid Leukemia Research 57
- Genetics 285
- Chronic Lymphocytic Leukemia Research 236
- Myeloproliferative Neoplasms: Diagnosis and Treatment 56
- Co-authors
- Brian Druker (117 shared papers)John M. Goldman (18 shared papers)Junia V. Melo (15 shared papers)Thomas O’Hare (82 shared papers)Christopher A. Eide (26 shared papers)Elisabeth Buchdunger (1 shared paper)Amie S. Corbin (22 shared papers)Jörge E. Cortes (80 shared papers)
- Journals
- Blood (164 papers)Journal of Clinical Oncology (31 papers)Leukemia (29 papers)Cancer Research (10 papers)Experimental Hematology (9 papers)
- Partner nations
- United StatesGermanyUnited Kingdom
In The Last Decade
Michael W. Deininger
387 papers receiving 20.8k citations
Michael W. Deininger's Hit Papers
Peers
Comparison fields: 5 of 133
- Hematology 15.8k
- Genetics 10.7k
- Rheumatology 6.4k
- Oncology 2.8k
- Pathology and Forensic Medicine 1.2k
Countries citing papers authored by Michael W. Deininger
This map shows the geographic impact of Michael W. Deininger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael W. Deininger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael W. Deininger more than expected).
Fields of papers citing papers by Michael W. Deininger
This network shows the impact of papers produced by Michael W. Deininger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael W. Deininger. The network helps show where Michael W. Deininger may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael W. Deininger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 400 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The molecular biology of chronic myeloid leukemia Hit paper breakdown → | 2000 | 1236 |
| 2 | The development of imatinib as a therapeutic agent for chronic myeloid leukemia Hit paper breakdown → | 2004 | 965 |
| 3 | Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet Hit paper breakdown → | 2009 | 892 |
| 4 | In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants Hit paper breakdown → | 2005 | 814 |
| 5 | Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia Hit paper breakdown → | 2017 | 814 |
| 6 | Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Hit paper breakdown → | 2000 | 615 |
| 7 | Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity Hit paper breakdown → | 2010 | 590 |
| 8 | Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2012 | 531 |
| 9 | 1997 | 499 | |
| 10 | 2007 | 468 | |
| 11 | International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Hit paper breakdown → | 2009 | 446 |
| 12 | 2006 | 377 | |
| 13 | 2008 | 375 | |
| 14 | 2003 | 361 | |
| 15 | OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML Hit paper breakdown → | 2013 | 360 |
| 16 | Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial Hit paper breakdown → | 2017 | 326 |
| 17 | Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia Hit paper breakdown → | 2015 | 325 |
| 18 | 1998 | 323 | |
| 19 | 2006 | 319 | |
| 20 | 2003 | 290 |
About Michael W. Deininger
Michael W. Deininger is a scholar working on Hematology, Genetics, Rheumatology, Molecular Biology and Public Health, Environmental and Occupational Health, having authored 400 papers that have together received 21.4k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (322 papers), Chronic Lymphocytic Leukemia Research (236 papers), Eosinophilic Disorders and Syndromes (132 papers), Acute Myeloid Leukemia Research (57 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (56 papers), Acute Lymphoblastic Leukemia research (43 papers), Mast cells and histamine (30 papers) and Click Chemistry and Applications (23 papers). The work is most often cited by research in Hematology (15.8k citations), Genetics (10.7k citations), Rheumatology (6.4k citations), Oncology (2.8k citations) and Pathology and Forensic Medicine (1.2k citations). Michael W. Deininger has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Brian Druker, John M. Goldman, Junia V. Melo, Thomas O’Hare, Christopher A. Eide, Elisabeth Buchdunger, Amie S. Corbin, Jörge E. Cortes, Andreas Hochhaus and Marc Loriaux. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, Cancer Research and Experimental Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.